leadf
logo-loader
viewLexaGene Holdings Inc.
(
TSX-V:LXGOTCQB:LXXGF
)

Full interview: LexaGene hits milestone by having pre-commercial device in hospital testing

LexaGene (CVE: LXG- OTCQB: LXXGF) CEO Dr Jack Regan joined Steve Darling from Proactive Vancouver with news the company now has one of their devices that tests for COVID-19 and other respiratory pathogens being used at the Dartmouth-Hitchcock Medical Center in Hanover, New Hampshire.

Regan talks about the lab it is being tested in and some of the key metrics they are looking for.

Quick facts: LexaGene Holdings Inc.

Follow
TSX-V:LXG

Price: 0.405 CAD

Market Cap: $48.14 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

LexaGene MiQLab on display as the company highlights unique features at WVC...

LexaGene CEO Dr. Jack Regan joined Steve Darling from Proactive on the floor of the 93rd annual WVC conference. This conference in Las Vegas is a gathering of veterinary marketplace leaders. Regan, who is a highlight speaker at the event, shared more with Proactive about his topic “In-Clinic...

2 weeks, 4 days ago

2 min read